Verified email-pattern data for Evathera Theranostics is currently limited. You can still use the company insights and contact sections below.
As cancer rates rise globally, highly effective, safe, patient-centric treatment options are more critical.
The EvaThera Theranostics platform of Molecular Targeting Technologies, Inc. contains a new generation of Evans Blue-based radiopharmaceuticals with strong affinity for albumin which:
• Extend the blood half-life of the targeting radiopeptides
• Decrease their blood clearance and improve uptake with less toxicity
• Promise improved therapeutic and diagnostic outcomes in SSTR2 and integrin expressing cancer patients.
Therapeutics targeting SST receptor subtype 2 (SSTR-2) protein expressing tumors, like Neuroendocrine Tumors (NETs) and Hürthle cell thyroid cancer, show comparatively low response rates, due in part to rapid blood clearance and cautious dosing to avoid potential renal toxicity.
EBTATE (177Lu-DOTA-EB-TATE) is a long-acting somatostatin analogue, an innovative “three-in-one” therapeutic, composed of a targeting octreotate peptide, modified Evans blue dye to improve biodistribution and chelator carrying a tumor killing radionuclide (177Lu). Trial results show improved safety and efficacy with fewer, lower doses than competing treatments with objective responses achieved after a single injection.
EBRGD is an Evans Blue modified RGD 177Lu peptide targeting integrin αvß3. It was developed to treat integrin expressing cancers like Glioblastoma Multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC). Today, there are 17,000 new US GBM diagnoses annually with median survival of only 15-16 months post-surgery. Prolonged circulation half-life delivers good, highly targeted tumor uptake of a diagnostic 64Cu EBRGD in a GBM human trial, holding out promise for a 177Lu therapeutic. Preclinical studies with 177Lu-EBRGD in tandem with a PD-L1 checkpoint inhibitor immunotherapy show significant synergy in decreased colorectal tumor volume and extended survival.
Company Details
- Founded
- -
- Address
- 833 Lincoln Ave,
- Industry
- Pharmaceutical Manufacturing
- Website
- http://www.evathera.com/
- Keywords
- Show more similar pages.
- HQ
- West Chester, Pennsylvania
Evathera Theranostics Questions
EvaThera Theranostics's website is http://www.evathera.com/
EvaThera Theranostics's LinkedIn profile is https://www.linkedin.com/company/evathera-theranostics
EvaThera Theranostics's industry is
Pharmaceutical Manufacturing
EvaThera Theranostics's top competitors are
Capella Imaging, Inc.,
Abdera Therapeutics,
Molecular Targeting Technologies,inc,
Molecular Targeting Technology, Inc.,
Artbio,
Alpha-9 Oncology,
Cell Eleven,
Verrica Pharmaceuticals,
Nuclidx,
Tac (Tacpharma.com).
EvaThera Theranostics's categories are Pharmaceutical Manufacturing
EvaThera Theranostics's founding year is 2011
Explore related pages
Related company profiles:
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.